BioSight
Companies
LEXICON PHARMACEUTICALS, INC. logo

LXRX

NASDAQTHE WOODLANDS, TX
LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals is a biopharmaceutical company developing small molecule oral drugs targeting cardiovascular, metabolic, and pain disorders. Its most advanced asset is sotagliflozin (INPEFA), already approved and commercialized for heart failure and type 2 diabetes with chronic kidney disease, with an ongoing Phase 3 trial in hypertrophic cardiomyopathy and a pending resubmission for type 1 diabetes; pilavapadin for neuropathic pain has completed two Phase 2 trials with positive results and Fast Track designation. Lexicon has licensed its obesity candidate LX9851 to Novo Nordisk and maintains a pipeline of earlier-stage programs derived from internal discovery efforts targeting validated genetic pathways.

Price history not yet available for LXRX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar